The 1980s legislation may not have achieved all its framers hoped, but it can be revised and improved for the 21st century
The savings policymakers usually claim for these projects are illusory, but well‐designed contracts can deliver public benefits.
Investors and corporations could benefit from less frequent reporting.
Claims that drug innovators extend their patents obscure a radical policy‐making goal.
Alberto Alesina, 1957–2020